
Chief Strategy Officer · Avalo Therapeutics, Inc. · Common Stock
Grant or award — administrative, little informational value
No reported dollar value · 1288.1% of prior position
Disclosed 3 business days after execution (deadline: 2)
First recorded trade by this actor in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | Philip Ron MDirector | Grant or award | A | $14K 1,109 sh | Oct 2, 2026 traded Sep 30, 2026 | |
| 9 | Sullivan Christopher RyanChief Financial Officer | Open-market sale · 10b5-1 plan | SELL | $202K 12.4K sh | Sep 18, 2026 traded Sep 16, 2026 | |
| 0 | Sullivan Christopher RyanChief Financial Officer | Option exercise · 10b5-1 plan | M | — 12.4K sh | Sep 18, 2026 traded Sep 16, 2026 | |
| 3 | Sullivan Christopher RyanChief Financial Officer | Option exercise · 10b5-1 plan | M | $122K 12.4K sh | Sep 18, 2026 traded Sep 16, 2026 | |
| 0 | Sullivan Christopher RyanChief Financial Officer | Option exercise · 10b5-1 plan | M | — 10.2K sh | Sep 11, 2026 traded Sep 10, 2026 | |
| 3 | Sullivan Christopher RyanChief Financial Officer | Option exercise · 10b5-1 plan | M | $82K 10.2K sh | Sep 11, 2026 traded Sep 10, 2026 | |
| 14 | Sullivan Christopher RyanChief Financial Officer | Open-market sale · 10b5-1 plan | SELL | $179K 10.2K sh | Sep 11, 2026 traded Sep 10, 2026 | |
| 0 | Doyle MittieChief Medical Officer | Option exercise · 10b5-1 plan | M | $5,459 679 sh | Sep 1, 2026 traded Aug 28, 2026 | |
| 0 | Doyle MittieChief Medical Officer | Option exercise · 10b5-1 plan | M | — 679 sh | Sep 1, 2026 traded Aug 28, 2026 | |
| 3 | Doyle MittieChief Medical Officer | Open-market sale · 10b5-1 plan | SELL | $14K 679 sh | Sep 1, 2026 traded Aug 28, 2026 | |
| 0 | Doyle MittieChief Medical Officer | Option exercise · 10b5-1 plan | M | — 1,000 sh | Aug 19, 2026 traded Aug 17, 2026 | |
| 15 | Sullivan Christopher RyanChief Financial Officer | Open-market sale · 10b5-1 plan | SELL | $75K 3,749 sh | Aug 19, 2026 traded Aug 17, 2026 | |
| 10 | Sullivan Christopher RyanChief Financial Officer | Option exercise · 10b5-1 plan | M | $307K 31.0K sh | Aug 19, 2026 traded Aug 18, 2026 | |
| 0 | Sullivan Christopher RyanChief Financial Officer | Option exercise · 10b5-1 plan | M | — 37.9K sh | Aug 19, 2026 traded Aug 17, 2026 | |
| 0 | Sullivan Christopher RyanChief Financial Officer | Option exercise · 10b5-1 plan | M | — 2,876 sh | Aug 19, 2026 traded Aug 17, 2026 | |
| 22 | Sullivan Christopher RyanChief Financial Officer | Open-market sale · 10b5-1 plan | SELL | $753K 37.9K sh | Aug 19, 2026 traded Aug 17, 2026 | |
| 10 | Sullivan Christopher RyanChief Financial Officer | Option exercise · 10b5-1 plan | M | $375K 37.9K sh | Aug 19, 2026 traded Aug 17, 2026 | |
| 0 | Doyle MittieChief Medical Officer | Option exercise · 10b5-1 plan | M | $13K 1,000 sh | Aug 19, 2026 traded Aug 17, 2026 | |
| 8 | Doyle MittieChief Medical Officer | Open-market sale · 10b5-1 plan | SELL | $20K 1,000 sh | Aug 19, 2026 traded Aug 17, 2026 | |
| 0 | Sullivan Christopher RyanChief Financial Officer | Option exercise · 10b5-1 plan | M | $28K 2,876 sh | Aug 19, 2026 traded Aug 17, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Riley Jennifer filed this Form 4 reporting a grant or award of AVTX on May 21, 2026. It became public on May 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.